SEC EDGARSEP 211 min read$SDGR

Akinsanya Karen sold $928K of SDGR

Akinsanya Karen (See Remarks) sold 31,599 shares of Schrodinger, Inc. (SDGR) at an average of $29.37 ($28.00–$30.00, $0.93M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Akinsanya Karen

Published Sep 21, 2026, 9:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 21, 2026, 9:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$SDGR

Bearish

medium confidence

Mentioned

$SDGR

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$SDGRBearishLow

Why it matters

The transaction may prompt short‑term selling pressure but is unlikely to move the stock significantly.

Market read

New insider sale information for SDGR; modest size, limited trading impact.

What to watch

Potential upcoming milestones or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Sep 21

Background

Form 4 filing reveals an officer's sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SDGRBearishMedium confidence

Context

Officer Akinsanya Karen sold 31,599 shares for $928K via a 10b5-1 plan, reducing her stake to 69,956 shares.

Expected impact

Slight short-term price dip expected.

Evidence & confidence

Sale size is modest but the insider is an officer; market may interpret as lack of confidence.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

No regional effect beyond the stock.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

Company
Schrodinger, Inc.
Biotech firm (ticker SDGR) subject of the insider sale.
Officer
Akinsanya Karen
Insider who sold shares.

Read at source ← All news

SEP 9

$SDGRMed

SDGR Looks 19.2% Undervalued on GF Value™

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.

gurufocus.com2 min

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 12

$SDGRMed

Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 Profitability - Has The Bull Case Changed?

Schrödinger (SDGR) reported Q2 2026 revenue of $58.89M, turning from a prior-year loss to net income of $5.98M, and filed a $46.95M shelf registration for 3,000,000 shares tied to its ESOP. Bristol Myers Squibb said it will deploy Schrödinger’s agentic AI co-scientist Bunsen across its research organization, expanding their collaboration.

simplywall.st6 min

AUG 5

$SDGRHigh

Schrodinger, Inc. (SDGR): Results of Operations and Financial Condition

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Second Quarter 2026 Financial Results Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery New York, August 5, 2026 – Schrödinger, Inc. (Nasdaq: S

SEC EDGAR 8-K6 min

SEP 26

$CRWDMed

Podbere Burt W. sold $83.5M of CRWD

Podbere Burt W. (CHIEF FINANCIAL OFFICER) sold 320,000 shares of CrowdStrike Holdings, Inc. (CRWD) at an average of $260.82 ($259.35–$262.29, $83.46M total) across 4 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

SEC EDGAR1 min